SEC Form 4 · accession 0001187159-26-000002
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent Milano
Director
Period of report
Jun 4, 2026
Accepted (ET)
Jun 8, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001557746
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 5, 2026 | M | 11,580 | — | A | 28,896 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3,F2 | $4.71 | Jun 4, 2026 | A | 42,350 | A | — | Jun 3, 2036 | Common Stock | 42,350 | 42,350 | D |
| Restricted Stock UnitsF3,F1,F4 | — | Jun 4, 2026 | A | 10,987 | A | — | — | Common Stock | 10,987 | 10,987 | D |
| Restricted Stock UnitsF1,F5 | — | Jun 5, 2026 | M | 11,580 | D | — | — | Common Stock | 11,580 | 0 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- F2The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.
- F3This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
- F4The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
- F5The shares underlying these restricted stock units vested on June 5, 2026.